The European Commission adopted Regulation (EU) 2026/1828 on July 28, 2026. It establishes maximum levels for the combined amount of delta-9-THC and THCA in hemp leaves intended for water infusion and in prepared hemp leaf infusions.

The rule applies from January 1, 2027. Foods lawfully placed on the market before that date may remain until their minimum durability or use-by date, giving businesses a defined transition rather than an immediate removal requirement.

Do not read hemp as a guarantee of zero THC. Keep the package, follow preparation instructions, and avoid driving or safety-sensitive activity if a product causes sedation, altered attention, dizziness, anxiety, or other unexpected effects.

Store loose leaves and prepared beverages away from children and pets. A food product can still matter clinically when it is used repeatedly, combined with other cannabinoids, or taken alongside medicines that affect alertness.

Ask about the specific tea, serving size, steeping method, frequency, other cannabis products, alcohol, sedatives, and the timing of symptoms. The regulatory category does not reveal the patient’s actual exposure.

The new limit is not a dosing recommendation and does not demonstrate efficacy for sleep, pain, anxiety, or another symptom. Counseling should remain tied to the patient’s goal, response, adverse effects, and functional safety.

The EU is applying a contaminant-style framework to a narrow hemp food category. That approach differs from broad bans or general hemp definitions because it identifies the product, analytes, measurement expression, and application date.

Clearer rules can support more consistent manufacturing and testing, but real protection depends on sampling, laboratory quality, labeling, market surveillance, and enforcement.

The regulation does not establish that hemp infusions are clinically beneficial or appropriate for a particular person. It does not address every cannabinoid product sold as hemp.

It also does not prove that a product under the legal maximum will be subjectively effect-free for every consumer, especially with repeated servings or other sedating exposures.

Caution is especially important for children, pregnant or breastfeeding people, older adults, people with cardiovascular or psychiatric vulnerability, and anyone using sedating medicines. The rule itself does not create a safety clearance for these groups.

Unexpected intoxication, severe anxiety, chest pain, fainting, persistent vomiting, or suspected child exposure warrants prompt professional guidance based on symptom severity.

Legal limits are only as reliable as the sampling and analytical systems behind them. A compliant result from one batch does not prove uniformity across every package or every preparation.

Commercial claims may use the new rule to imply broader safety or medical legitimacy. The text supports a food-compliance claim for defined products, not a therapeutic claim.

Member states should publish practical laboratory guidance, enforcement expectations, and market-surveillance findings before the 2027 application date. Businesses need enough specificity to reformulate or document compliance without guessing.

Public reporting should distinguish noncompliance from adverse events and explain whether measured problems arise from raw material, processing, labeling, or preparation.

Governments increasingly separate industrial hemp foods from intoxicating hemp-derived cannabinoid products. This EU rule is unusually specific because it addresses leaves used for infusion rather than applying a broad plant definition alone.

For clinicians, the useful distinction is between a regulated concentration limit and a treatment recommendation. Product rules can reduce uncertainty, but they do not replace a medication review, symptom target, dose discussion, or assessment of impairment.

A tea can feel familiar and low-risk, which is exactly why precise labeling and testing matter. People may drink more than one cup, steep leaves differently, or combine the product with alcohol, sedatives, or other cannabinoids.

I would treat this as a useful food-safety improvement, not a medical endorsement. If a patient reports benefit or an unexpected effect, document the actual product, preparation, amount, timing, and co-exposures before drawing conclusions.

Four distinctions that matter